# WellDoc

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/welldoc

- Industry: Healthcare IT
- Headquarters: Columbia, US
- Website: www.welldoc.com
- Total disclosed funding: $45M
- Latest round: Series B (Mar 1, 2016)
- Investors on record: 9

## About

WellDoc, Inc. delivers innovative digital health solutions, including the FDA-cleared BlueStar app, designed to assist users in managing chronic conditions like diabetes and hypertension through personalized insights.Founded in 2005, WellDoc, Inc. is headquartered in Columbia, US, focusing on digital health solutions. The company successfully raised USD 7.5 mn in a Series B funding round on March 1, 2016, led by Johnson & Johnson Innovation. The firm has completed a total of 11 deals to date.WellDoc specializes in digital health solutions, primarily through its flagship product, BlueStar, an FDA-cleared mobile application for managing chronic conditions such as Type 1 and Type 2 diabetes, hypertension, heart failure, and obesity. The platform utilizes artificial intelligence to provide personalized, actionable insights that empower users and their care teams in achieving improved health outcomes. Through data-driven insights, WellDoc addresses the needs of individuals with chronic conditions by enabling self-management and facilitating communication with healthcare providers. The company serves a diverse client base, including health plans, health systems, employers, and partners, targeting markets across the United States. Additionally, WellDoc has established partnerships to expand the reach of its services, thereby enhancing the overall health ecosystem.WellDoc generates revenue through a combination of subscription models and partnerships with healthcare systems and employers. The structure of transactions is designed to provide scalable solutions that address the needs of both individual users and healthcare organizations. Clients may pay for access to the BlueStar platform through various pricing plans tailored to their specific requirements, which may include subscriptions for health plans and employers looking to manage chronic care. As part of its strategic collaborations, WellDoc enhances its offerings to clients, ensuring that healthcare providers can effectively deliver care while also benefiting from potential cost savings associated with improved health outcomes for their members.Following the recent funding round of USD 7.5 mn in March 2016, WellDoc aims to expand its market presence and enhance its product offerings. The company is focusing on the development of new features for the BlueStar app and plans to broaden its reach into additional healthcare sectors and geographic markets across the United States. WellDoc is strategically positioned to leverage its funding to support these growth initiatives and improve accessibility to its digital health solutions.

## Funding rounds

- Series B, Mar 1, 2016, $7.5M — Johnson & Johnson Innovation
- Series B, Dec 16, 2015, $22M — Alexandria Venture Investments, Adage Capital Management, Excel Venture Management, Merck Global Health Innovation Fund, Samsung Venture Investment, Hudson River Ventures, LLC
- Series A, Jan 9, 2014, $16M — Merck Global Health Innovation Fund, Windham Venture Partners
- Seed, Apr 1, 2007, $0.1M — TCP Venture Capital

## Investors

- TCP Venture Capital (https://capitalatlas.ai/funds/tcp-venture-capital) — Seed
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A, Series B
- Windham Venture Partners (https://capitalatlas.ai/funds/windham-venture-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Adage Capital Management — Series B
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series B
- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series B
- Hudson River Ventures, LLC — Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B